1Fisher B,Mamounas EP.Preoperative chemotherapy:a model for studying the biology and therapy of primary breast cancer[J].J Clin Oncol,1995,13(3):537-540.
3Swain SW,Sorace RA,Bagley CS,et al.Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer[J].Cancer Res,1987,47(12):3 889-3 894.
4Buzdar AU,Singletary SE,Theriault RL,et al.Prospective evaluation of paclitaxe versus combination chemotherapy with fluorouracil,doxorubicin and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer[J].J Clin Oncol,1999,17(11):3 412-3 417.
5Smith IC.Neoadjuvant chemotherapy in breast cancer:significantly enhanced with docetaxel[J].J Clin Oncol,2002,20(6):1 456.
7Fisher B,Brown A,Mamounas E,et al.Effect of preoperative chemotherapy on local-regional diseases in women with operable breast cancer:finding from nation surgical adjuvant and bowel project B-18[J].J Clin Oncol,1997,15(7):2 483-2 493.
2Bhalla K, Harris WB. Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer. Semin Oncol, 1998, 25 (2 suppl 3): 19-24.
3Kuerer HM, Newman LA, Buzder AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg, 1998, 176:502-509.
4Ellis P, Smith I, Ashley S, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol, 1998, 16:107-114.
5Cameron DA, Anderson ED, Levack P, et al. Primary systemic therapy for operable breast cancer - 10 - year survival data after chemotherapy and hormone therapy. Br J Cancer, 1997, 76:1099-1105.
6Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer, 2000, 83: 1480-1487.
7Hutcheon AW, Heys SD, Miller ID, et al. Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: a randomised controlled trial. Breast Cancer Res Treat, 2001, 69: 298.
8Chang J, Ormerod M, Powles TJ, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer, 2000, 89: 2145-2152.
9Bottini A, Berruti A, Bersiga A, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res, 2000,6: 2751-2758.
10Akashi-Tanaka S, Fukutomi T, Watanabe T, et al. Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int J Cancer, 2001, 96: 66-73.
3Bleyer A.Young adult oncology: the patients and their survival challenges[J]. C A CancerJ Clin, 2007, 57(4): 242-255.
4FisherB, GunduzN, Saffer E A.Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases[J]. CancerRes, 1983, 43(4): 1488-1492.
5Gunduz N, Fisher B, Saffer E A.Effect of surgical removal on the growth andkineticsofresidualtumor[J].CancerRes, 1979, 39(10): 3861-3865.
6Erol K, Baltali E, Altundag K, et al.Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer[J].Onkologie, 2005, 28(2): 81-85.
7Estevez L G, Senchez-Rovira P, Demine M, et al.Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage Ⅱ and Ⅲ breast cancer patients: results of a phase Ⅱ study[J].Clin Transl Oncol, 2007, 9(5): 317-322.
8Mouret R M A, Abrial C J, Ferriere J P, et al.Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at centre Jean perrin[J].Clin Breast Cancer, 2004, 5(4): 303-307.
9Andrade J M, Carrara H H, Pimentel F F, et al.Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage Ⅱ and Ⅲ breast cancer[J].Med Oncol, 2010, 16(10): 1007.
10Strayer M E, Adrichem J C, Rutgers E J, et al.Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy[J].Ned Tijdschr Geneeskd, 2008, 152(46): 2519-2525.
